Search the archive.

Add

2026 2026-27 NFA-LD Nationalization Negative

Negative evidence

National health spending outcomes depend on payment and use, not coverage alone.

Congressional Budget Office, How CBO Analyzes Proposals for a Single-Payer Health Care System, Working Paper 2020-08, December 2020, https://www.cbo.gov/publication/56811

Recent evidence
Sign in to open up to 10 recent cards daily.

Read card Source

Add

2026 2026-27 NFA-LD Nationalization Negative

Negative evidence

Single payer expands use but can increase congestion when supply responds slowly.

Congressional Budget Office, How CBO Analyzes Proposals for a Single-Payer Health Care System, Working Paper 2020-08, December 2020, https://www.cbo.gov/publication/56811

Recent evidence
Sign in to open up to 10 recent cards daily.

Read card Source

Add

2026 2026-27 NFA-LD Nationalization Kritik

Negative evidence

Interstate infrastructure planning must account for tribal jurisdiction and consent.

U.S. Department of Energy, Tribal Energy Sovereignty, https://www.energy.gov/indianenergy/tribal-energy-sovereignty

Recent evidence
Sign in to open up to 10 recent cards daily.

Read card Source

Add

2026 2026-27 NFA-LD Nationalization Kritik

Negative evidence

Centralized health administration creates both universal capacity and classificatory power.

Congressional Budget Office, Key Design Components and Considerations for Establishing a Single-Payer Health Care System, May 1, 2019, https://www.cbo.gov/publication/55150

Recent evidence
Sign in to open up to 10 recent cards daily.

Read card Source

Add

2026 2026-27 NFA-LD Nationalization Kritik

Negative evidence

Weapons acquisition reform can normalize military purpose by making violence appear efficient and accountable.

Julia Gledhill, Recognizing Reality: A Case for Nationalizing the US Arms Industry, Stimson Center, September 2025, https://www.stimson.org/2025/recognizing-reality-a-case-for-nationalizing-the-us-arms-industry/

Recent evidence
Sign in to open up to 10 recent cards daily.

Read card Source

Add

2026 2026-27 NFA-LD Nationalization Kritik

Negative evidence

Nationalization during crisis can socialize private losses while protecting accumulation.

Massimo Florio, The Return of Public Enterprise, 2014, https://www.jstor.org/stable/10.2307/j.ctt9qf0q3

Recent evidence
Sign in to open up to 10 recent cards daily.

Read card Source

Add

2026 2026-27 NFA-LD Nationalization Kritik

Negative evidence

Public ownership can preserve market discipline instead of displacing neoliberal governance.

David A. McDonald, editor, Making Public in a Privatized World: The Struggle for Essential Services, Zed Books, 2016, https://www.tni.org/en/publication/making-public-in-a-privatized-world

Recent evidence
Sign in to open up to 10 recent cards daily.

Read card Source

Add

2026 2026-27 NFA-LD Nationalization Negative

Negative evidence

H.R. 6607 uses procurement commitments because manufacturing ownership alone does not finance capacity.

118th Congress, H.R. 6607, Affordable Drug Manufacturing Act of 2023, introduced December 5, 2023, https://www.congress.gov/bill/118th-congress/house-bill/6607/text

Recent evidence
Sign in to open up to 10 recent cards daily.

Read card Source

Add

2026 2026-27 NFA-LD Nationalization Negative

Negative evidence

Public manufacturing must still comply with FDA quality and bioequivalence requirements.

U.S. Food and Drug Administration, Overview and Basics: Generic Drugs, https://www.fda.gov/drugs/generic-drugs/overview-basics

Recent evidence
Sign in to open up to 10 recent cards daily.

Read card Source

Add

2026 2026-27 NFA-LD Nationalization Negative

Negative evidence

Additional qualified competitors lower prices, regardless of ownership.

U.S. Food and Drug Administration, Generic Drug Facts, updated 2026, https://www.fda.gov/drugs/generic-drugs/generic-drug-facts

Recent evidence
Sign in to open up to 10 recent cards daily.

Read card Source

Add

2026 2026-27 NFA-LD Nationalization Negative

Negative evidence

Quality failures and capacity constraints—not legal authority alone—drive shortages.

U.S. Government Accountability Office, Drug Shortages, GAO-25-107110, April 9, 2025, https://www.gao.gov/products/gao-25-107110

Recent evidence
Sign in to open up to 10 recent cards daily.

Read card Source

Add

2026 2026-27 NFA-LD Nationalization Affirmative

1AC evidence

National health spending need not rise even while coverage and use expand.

Congressional Budget Office, How CBO Analyzes Proposals for a Single-Payer Health Care System, Working Paper 2020-08, December 2020, https://www.cbo.gov/publication/56811

Recent evidence
Sign in to open up to 10 recent cards daily.

Read card Source

Add

2026 2026-27 NFA-LD Nationalization Affirmative

1AC evidence

Administrative savings and greater population health can raise productive capacity.

Congressional Budget Office, Economic Effects of Five Illustrative Single-Payer Health Care Systems, February 2022, https://www.cbo.gov/publication/57637

Recent evidence
Sign in to open up to 10 recent cards daily.

Read card Source

Add

2026 2026-27 NFA-LD Nationalization Affirmative

1AC evidence

Consolidated insurance administration creates large savings unavailable to multipayer reform.

Congressional Budget Office, Key Design Components and Considerations for Establishing a Single-Payer Health Care System, May 1, 2019, https://www.cbo.gov/publication/55150

Recent evidence
Sign in to open up to 10 recent cards daily.

Read card Source

Add

2026 2026-27 NFA-LD Nationalization Affirmative

1AC evidence

Comprehensive benefits solve underinsurance instead of merely changing the insurance card.

119th Congress, H.R. 3069, Medicare for All Act, introduced April 29, 2025, https://www.congress.gov/bill/119th-congress/house-bill/3069/text

Recent evidence
Sign in to open up to 10 recent cards daily.

Read card Source

Add

2026 2026-27 NFA-LD Nationalization Affirmative

1AC evidence

Federal purchasing commitments make resilient capacity financeable.

118th Congress, H.R. 6607, Affordable Drug Manufacturing Act of 2023, introduced December 5, 2023, https://www.congress.gov/bill/118th-congress/house-bill/6607/text

Recent evidence
Sign in to open up to 10 recent cards daily.

Read card Source

Add

2026 2026-27 NFA-LD Nationalization Affirmative

1AC evidence

Generic competition improves adherence and health by making treatment affordable.

U.S. Food and Drug Administration, Prescriber Stakeholder Toolkit, https://www.fda.gov/drugs/generic-drugs/prescriber-stakeholder-toolkit-sample-blog-postnewsletter-article

Recent evidence
Sign in to open up to 10 recent cards daily.

Read card Source

Add

2026 2026-27 NFA-LD Nationalization Affirmative

1AC evidence

Competition sharply lowers generic-drug prices.

U.S. Food and Drug Administration, Generic Drug Facts, updated 2026, https://www.fda.gov/drugs/generic-drugs/generic-drug-facts

Recent evidence
Sign in to open up to 10 recent cards daily.

Read card Source

Add

2026 2026-27 NFA-LD Nationalization Affirmative

1AC evidence

Public API capacity reduces exposure to single-source and offshore disruption.

118th Congress, H.R. 6607, Affordable Drug Manufacturing Act of 2023, introduced December 5, 2023, https://www.congress.gov/bill/118th-congress/house-bill/6607/text

Recent evidence
Sign in to open up to 10 recent cards daily.

Read card Source

Add

2026 2026-27 NFA-LD Nationalization Affirmative

1AC evidence

Medicare-X preserves continuity while creating structural public capacity.

Senator Tim Kaine, Medicare-X Choice Act bill summary, 2025, https://www.kaine.senate.gov/imo/media/doc/medicare-x-choice-act-bill-summary-2025.pdf

Recent evidence
Sign in to open up to 10 recent cards daily.

Read card Source